Pool Global Partners

Oncoustics is focused on enhancing clinical workflow productivity through the development and deployment of advanced artificial intelligence solutions for non-invasive disease monitoring. The company utilizes AI to analyze raw ultrasound signals from accessible handheld devices, enabling rapid differentiation between healthy and diseased tissues. This innovative approach uncovers novel acoustic biomarkers that align with established medical standards. Initially concentrating on liver disease, which represents a significant global diagnostic market, Oncoustics has pursued Breakthrough Device Designation from the FDA for its OnX device, designed to detect liver fibrosis, and is progressing with a 510K filing. The company is also advancing several additional liver-related products and has gathered clinical data on various other organ conditions, including prostate, kidney, breast, and thyroid diseases and cancers.

Modl.ai provides innovative gaming technology designed to streamline game development and improve player engagement. The company focuses on empowering game developers and publishers by transforming the production process through the use of artificial intelligence and machine learning. Its platform automates repetitive tasks and enhances in-game behaviors and simulations, allowing publishers to elevate game quality and user experience while increasing operational efficiency.

Prescryptive Health, Inc. is a digital health company that operates a prescription benefits platform aimed at enhancing the accessibility and affordability of medications for both payers and patients. Established in 2017 and based in Redmond, Washington, the company provides services that include analyzing current plan designs, recommending new plans, and facilitating member enrollment. Its platform empowers users by offering direct access to market pricing, unbiased information, and real-time cost insights regarding prescribed treatments. This includes details on insurance coverage, out-of-pocket expenses, and available lower-cost alternatives. Prescryptive Health serves a diverse range of clients, including employers, health plans, providers, pharmacies, and pharmaceutical companies, with the goal of democratizing the prescription drug market.

Acorn Biolabs, Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in providing a take-home human cell cryopreservation service that focuses on non-invasive, follicle-based cell collection methods. Acorn Biolabs aims to preserve healthy young cells for potential future use in regenerative treatments, including gene therapies and stem cell therapeutics. Its services are accessible directly to consumers through both at-home and in-clinic collections, and the company partners with various clinics and pharmacies to expand its reach across Canada.

RentLogic Corporation operates a platform that assesses and rates the quality of multi-family residential buildings in New York City, grading approximately 1.1 million apartment buildings based on health and safety standards. The grading system categorizes buildings into four levels: A, B, C, or F, derived from physical inspections and public data from city agencies. Founded in 2013 and based in New York, RentLogic aims to provide an objective and credible evaluation methodology developed in collaboration with various housing sector stakeholders. The platform not only assists building owners who prioritize quality management but also helps residents navigate the challenging rental market by facilitating connections between them and responsible property owners.

Tread, Inc. is a Toronto-based company founded in 2016 that specializes in developing a platform for managing construction equipment services. The platform facilitates interaction among contractors, brokers, and operators, simulating a unified fleet experience. By leveraging data analytics, Tread enables construction companies to hire equipment-operating subcontractors effectively. Its software provides real-time recording and measurement of equipment usage, allowing clients to identify opportunities for cost savings and optimize operational efficiency in construction projects.

MIMOSA Diagnostics Inc. is a Toronto-based company established in 2016 that specializes in the development of a multispectral mobile tissue assessment device. The company's flagship product, the MIMOSA Pro, is a handheld device that utilizes near-infrared light to non-invasively evaluate tissue health by visualizing biomarkers such as oximetry and temperature beneath the skin's surface, regardless of skin color. This technology aims to enhance patient care by providing immediate insights that can inform treatment decisions, thereby improving outcomes for patients, particularly for those with diabetes who need to monitor their foot health. The device is designed for easy use by both patients and caregivers, streamlining the process of assessing tissue health without the need for extensive testing or long wait times.

Plantiga Technologies Inc. is a Vancouver-based company that specializes in biometric sensing technology for footwear. Founded in 2017, Plantiga has developed a platform that offers human movement intelligence, providing deep insights into health by analyzing how individuals move. Their technology focuses on optimizing health, preventing injuries, and monitoring recovery by detecting subtle changes in functional movement patterns that are often imperceptible. By combining rigorous analysis of human performance with wearable device capabilities, Plantiga enables users to assess athletic performance, health, and productivity effectively.

InnerSpace is a space utilization platform that helps large enterprises make smarter decisions about using corporate real estate. Our powerful technology leverages a company's existing Wi-Fi infrastructure to provide unrivaled, multi-dimensional data without all the cost and effort needed for traditional sensor-based systems.

Oncoustics is focused on enhancing clinical workflow productivity through the development and deployment of advanced artificial intelligence solutions for non-invasive disease monitoring. The company utilizes AI to analyze raw ultrasound signals from accessible handheld devices, enabling rapid differentiation between healthy and diseased tissues. This innovative approach uncovers novel acoustic biomarkers that align with established medical standards. Initially concentrating on liver disease, which represents a significant global diagnostic market, Oncoustics has pursued Breakthrough Device Designation from the FDA for its OnX device, designed to detect liver fibrosis, and is progressing with a 510K filing. The company is also advancing several additional liver-related products and has gathered clinical data on various other organ conditions, including prostate, kidney, breast, and thyroid diseases and cancers.

Miovision is a developer of a traffic management platform that specializes in collecting and analyzing both in-house and outsourced traffic data to enhance traffic signal operations. The company offers intelligent technology solutions aimed at addressing the challenges of modern transportation networks while reducing the environmental impacts of inefficient traffic flow. By utilizing computer vision and artificial intelligence, Miovision's platform enables municipalities to gather multimodal traffic data and derive actionable insights, ultimately improving the transportation experience for drivers, cyclists, and pedestrians alike. Its comprehensive approach facilitates the easy request, delivery, and analysis of traffic data, catering to the needs of data collectors, traffic consultants, and municipal governments.